Key facts
- It has raised $4.0M; the latest was Seed Round ($2.3M) in Jun 2025.
- Notable investors include StartLife, Oost NL, SHIFT Invest, Wageningen University & Research, GenDx — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Scope Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Scope Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scope Biosciences
Operator of a molecular diagnostics technology designed to enable accessible nucleic acid detection in healthcare and agriculture. The company's technology offers specificity in detecting single nucleotide differences, sensitivity to trace genetic material, and a format operable outside laboratory settings, enabling healthcare providers and agricultural professionals to make on-site decisions.
- Sector
- Healthcare
- HQ
- Wageningen, Netherlands
- Employees
- 12
- Website
- scopebio.com/
- Ownership
- Privately Held (backing)
Scope Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scope Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scope Biosciences in its N-PORT filings yet. We sweep new filings monthly.